Niko Kley is an accomplished scientist and biotech executive with a multifaceted track record in applied research, drug development, company building and high value biopharma partnerships. His work ranged from discoveries on root causes and drivers of hereditary and sporadic forms of cancer to pioneering specialized technologies for discovery and design of targeted small molecules, molecular glues, and conditionally acting biologics for novel immunotherapies. His work led to advancement of novel drug modalities into clinical trials and FDA approval. Niko was a co-founder of FORMA Therapeutics [acquired by Novo Nordisk in 2022] and has served as an executive scientific leader at various biotech organizations and pharma [BMS]. He was a Research Professor at the Dept. of Molecular Biology, Princeton University, completed a postdoctoral fellowship at Harvard Medical School (Massachusetts General Hospital), holds a PhD from the Max Planck Institute/Ludwig-Maximilian-University in Munich, and a BSc with Honors from Leeds University (UK). He (co)-authored over 65 peer reviewed scientific publications, various book chapters and dozens of patents. Niko received several awards, including the Otto Hahn Prize.